Pivotal Health

pivotalhealth.ai

+46%

est. 2Y upside i

Healthcare

Rank

#1819

Sector

Healthcare Technology

Est. Liquidity

~6Y

Data Quality

Data: Low

Pivotal Health has a credible setup — Bessemer-backed, large fast-growing TAM, and a strong regulatory moat via No Surprises Act IDR — but every critical financial data point (revenue, valuation, funding raised) is null, making it impossible to independently evaluate the preference stack or entry price.

Last updated: May 14, 2026

Bull (100%)+180%

Pivotal Health captures 1-2% of its $20B SAM (~$200-400M ARR) within 5-7 years at a 10-12x revenue multiple, reaching a $2-4B valuation; within 2 years, a Series B priced at 3-4x today's unknown baseline and strong ARR trajectory would yield roughly 180% paper upside for employees entering now.

Est. time to liquidity~6.0 years

Preference Stack Risk

moderate

Funding Intensity

0%

Total funding and current valuation are both null; with Bessemer as lead on a likely Seed-to-Series A stage company, estimated preferences of $5-20M against an unknown valuation make the overhang unquantifiable — treat as at least moderate until the cap table is disclosed.

Dilution Risk

high

As a 22-person company almost certainly pre-Series B, employees should expect 40-60%+ dilution from future financing rounds (Series A, B, C) before any liquidity event.

Secondary Liquidity

none

No secondary market exists for shares in a 22-person private company at this stage; employees should expect full lockup for an estimated 5-7 years until an IPO or acquisition.

Other 1 role

View all 1 open roles at Pivotal Health

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Pivotal Health's data — designed to show you've done your homework.

  • 1

    How has IDR claim volume and provider win-rate trended month-over-month since launch, and what share of submitted disputes does Pivotal Health successfully resolve in favor of providers?

  • 2

    What is the current ARR run rate and average revenue per resolved claim, and how does the success-based fee structure hold up if CMS narrows the categories of qualifying No Surprises Act disputes?

  • 3

    What is the current 409A valuation, total liquidation preference stack, and fully diluted cap table — and has the board discussed any secondary liquidity program or tender offer for employees?

Community

Valuation Sentiment

Our model estimates +46% upside. What do you think?

Anonymous. Do not share material non-public information.


Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.